BioLamina

BioLamina, established in 2009 and headquartered in Sweden, is carving a niche in the biotechnology industry by focusing on cell-specific culture matrices that enhance cell functionality. Their unique value proposition, encapsulated in the slogan, "Cell-specific culture matrices for improved cell functionality," underscores their commitment to innovation in cell culture research.

The cornerstone of their product line is Biolaminin® substrates, which have gained notable attention and validation through numerous scientific publications. By offering these advanced tools, BioLamina aims to streamline the cultivation of pluripotent stem cells and enhance the precision of cell assays and models, thus supporting the development of safer and more effective cell therapies and accelerating drug discovery efforts.

In a recent Venture Round investment on September 12, 2023, BioLamina secured €17.00M from investors including Lauxera Capital Partners, Northislet, and Bure Equity AB, highlighting sustained confidence in its growth trajectory and market potential.